Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 50 of 69

1.

3D MicroCT spatial and temporal characterization of thoracic aorta perivascular adipose tissue and plaque volumes in the ApoE-/- mouse model.

Faight E, Verdelis K, Ahearn JM, Shields KJ.

Adipocyte. 2018;7(3):156-165. doi: 10.1080/21623945.2018.1493900. Epub 2018 Aug 9.

2.

Study rationale, design, and pretransplantation alloantibody status: A first report of Clinical Trials in Organ Transplantation in Children-04 (CTOTC-04) in pediatric heart transplantation.

Zuckerman WA, Zeevi A, Mason KL, Feingold B, Bentlejewski C, Addonizio LJ, Blume ED, Canter CE, Dipchand AI, Hsu DT, Shaddy RE, Mahle WT, Demetris AJ, Briscoe DM, Mohanakumar T, Ahearn JM, Iklé DN, Armstrong BD, Morrison Y, Diop H, Odim J, Webber SA.

Am J Transplant. 2018 Sep;18(9):2135-2147. doi: 10.1111/ajt.14695. Epub 2018 Mar 23.

3.

Real-time imaging of yeast cells reveals several distinct mechanisms of curing of the [URE3] prion.

Zhao X, Lanz J, Steinberg D, Pease T, Ahearn JM, Bezsonov EE, Staguhn ED, Eisenberg E, Masison DC, Greene LE.

J Biol Chem. 2018 Mar 2;293(9):3104-3117. doi: 10.1074/jbc.M117.809079. Epub 2018 Jan 12.

4.

Cell-bound complement activation products as lupus biomarkers: diagnosis, monitoring and stratification.

Ahearn JM, Liu CC, Manzi S.

Expert Rev Clin Immunol. 2017 Dec;13(12):1133-1142. doi: 10.1080/1744666X.2017.1392238. Epub 2017 Nov 6. Review.

PMID:
29025354
5.

Potential Roles of Antiphospholipid Antibodies in Generating Platelet-C4d in Systemic Lupus Erythematosus.

Liu CC, Schofield T, Tang A, Manzi S, Ahearn JM.

Antibodies (Basel). 2017 Jul 2;6(3). pii: E9. doi: 10.3390/antib6030009.

6.

Association of aortic perivascular adipose tissue density with aortic calcification in women with systemic lupus erythematosus.

Shields KJ, El Khoudary SR, Ahearn JM, Manzi S.

Atherosclerosis. 2017 Jul;262:55-61. doi: 10.1016/j.atherosclerosis.2017.04.021. Epub 2017 Apr 29.

PMID:
28521185
7.

Heat shock protein 104 (Hsp104)-mediated curing of [PSI+] yeast prions depends on both [PSI+] conformation and the properties of the Hsp104 homologs.

Zhao X, Rodriguez R, Silberman RE, Ahearn JM, Saidha S, Cummins KC, Eisenberg E, Greene LE.

J Biol Chem. 2017 May 26;292(21):8630-8641. doi: 10.1074/jbc.M116.770719. Epub 2017 Apr 3.

8.

Plasma complement and vascular complement deposition in patients with coronary artery disease with and without inflammatory rheumatic diseases.

Shields KJ, Mollnes TE, Eidet JR, Mikkelsen K, Almdahl SM, Bottazzi B, Lyberg T, Manzi S, Ahearn JM, Hollan I.

PLoS One. 2017 Mar 31;12(3):e0174577. doi: 10.1371/journal.pone.0174577. eCollection 2017.

9.

Antilymphocyte autoantibodies generate T cell-C4d signatures in systemic lupus erythematosus.

Liu CC, Manzi S, Ahearn JM.

Transl Res. 2014 Dec;164(6):496-507. doi: 10.1016/j.trsl.2014.07.007. Epub 2014 Aug 7.

PMID:
25168018
10.

The lupus biomarker odyssey: one experience.

Ahearn JM, Manzi S, Liu CC.

Methods Mol Biol. 2014;1134:17-35. doi: 10.1007/978-1-4939-0326-9_2. Review.

PMID:
24497351
11.

Relation of platelet C4d with all-cause mortality and ischemic stroke in patients with systemic lupus erythematosus.

Kao AH, McBurney CA, Sattar A, Lertratanakul A, Wilson NL, Rutman S, Paul B, Navratil JS, Scioscia A, Ahearn JM, Manzi S.

Transl Stroke Res. 2014 Aug;5(4):510-8. doi: 10.1007/s12975-013-0295-9. Epub 2013 Oct 27.

PMID:
24323718
12.

Biomarkers in systemic lupus erythematosus: challenges and prospects for the future.

Liu CC, Kao AH, Manzi S, Ahearn JM.

Ther Adv Musculoskelet Dis. 2013 Aug;5(4):210-33. doi: 10.1177/1759720X13485503.

13.

Cardiovascular disease in autoimmune rheumatic diseases.

Hollan I, Meroni PL, Ahearn JM, Cohen Tervaert JW, Curran S, Goodyear CS, Hestad KA, Kahaleh B, Riggio M, Shields K, Wasko MC.

Autoimmun Rev. 2013 Aug;12(10):1004-15. doi: 10.1016/j.autrev.2013.03.013. Epub 2013 Mar 27. Review.

PMID:
23541482
14.

Complement fragment C3d is colocalized within the lipid rafts of T cells and promotes cytokine production.

Borschukova O, Paz Z, Ghiran IC, Liu CC, Kao AH, Manzi S, Ahearn JM, Tsokos GC.

Lupus. 2012 Oct;21(12):1294-304. Epub 2012 Jul 31.

PMID:
22851413
15.

Biomarkers for systemic lupus erythematosus.

Ahearn JM, Liu CC, Kao AH, Manzi S.

Transl Res. 2012 Apr;159(4):326-42. doi: 10.1016/j.trsl.2012.01.021. Epub 2012 Feb 10. Review.

PMID:
22424435
16.

Prospective assessment of C4d deposits on circulating cells and renal tissues in lupus nephritis: a pilot study.

Batal I, Liang K, Bastacky S, Kiss LP, McHale T, Wilson NL, Paul B, Lertratanakul A, Ahearn JM, Manzi SM, Kao AH.

Lupus. 2012 Jan;21(1):13-26. doi: 10.1177/0961203311422093. Epub 2011 Sep 29.

PMID:
21959138
17.

Complement proteins C3 and C4 bind to collagen and elastin in the vascular wall: a potential role in vascular stiffness and atherosclerosis.

Shields KJ, Stolz D, Watkins SC, Ahearn JM.

Clin Transl Sci. 2011 Jun;4(3):146-52. doi: 10.1111/j.1752-8062.2011.00304.x.

18.

Cell-bound complement biomarkers for systemic lupus erythematosus: from benchtop to bedside.

Liu CC, Manzi S, Kao AH, Navratil JS, Ahearn JM.

Rheum Dis Clin North Am. 2010 Feb;36(1):161-72, x. doi: 10.1016/j.rdc.2009.12.003.

19.

Erythrocyte C3d and C4d for monitoring disease activity in systemic lupus erythematosus.

Kao AH, Navratil JS, Ruffing MJ, Liu CC, Hawkins D, McKinnon KM, Danchenko N, Ahearn JM, Manzi S.

Arthritis Rheum. 2010 Mar;62(3):837-44. doi: 10.1002/art.27267.

20.

Lymphocyte-bound complement activation products as biomarkers for diagnosis of systemic lupus erythematosus.

Liu CC, Kao AH, Hawkins DM, Manzi S, Sattar A, Wilson N, Ahearn JM.

Clin Transl Sci. 2009 Aug;2(4):300-8. doi: 10.1111/j.1752-8062.2009.00135.x.

21.

Increased erythrocyte C4D is associated with known alloantibody and autoantibody markers of antibody-mediated rejection in human lung transplant recipients.

Golocheikine A, Nath DS, Basha HI, Saini D, Phelan D, Aloush A, Trulock EP, Hachem RR, Patterson GA, Ahearn JM, Mohanakumar T.

J Heart Lung Transplant. 2010 Apr;29(4):410-6. doi: 10.1016/j.healun.2009.10.003.

22.

The search for lupus biomarkers.

Liu CC, Ahearn JM.

Best Pract Res Clin Rheumatol. 2009 Aug;23(4):507-23. doi: 10.1016/j.berh.2009.01.008. Review.

23.

Platelet C4d is associated with acute ischemic stroke and stroke severity.

Mehta N, Uchino K, Fakhran S, Sattar MA, Branstetter BF 4th, Au K, Navratil JS, Paul B, Lee M, Gallagher KM, Manzi S, Ahearn JM, Kao AH.

Stroke. 2008 Dec;39(12):3236-41. doi: 10.1161/STROKEAHA.108.514687. Epub 2008 Oct 16.

PMID:
18927458
24.

Relative contributions of age and atherosclerosis to vascular stiffness.

Santelices LC, Rutman SJ, Prantil-Baun R, Vorp DA, Ahearn JM.

Clin Transl Sci. 2008 May;1(1):62-6. doi: 10.1111/j.1752-8062.2008.00014.x.

25.

Experimental system for ex vivo measurement of murine aortic stiffness.

Santelices LC, Calano SJ, Erhart JC, Prantil RL, Haney JL, Vorp DA, Ahearn JM.

Physiol Meas. 2007 Aug;28(8):N39-49. Epub 2007 Jul 6. Review.

PMID:
17664666
26.

Mannose-binding lectin is a disease-modifying factor in North American patients with systemic lupus erythematosus.

Piao W, Liu CC, Kao AH, Manzi S, Vogt MT, Ruffing MJ, Ahearn JM.

J Rheumatol. 2007 Jul;34(7):1506-13. Epub 2007 Jun 15.

PMID:
17610319
27.

Apoptosis and autoimmunity.

Navratil JS, Liu CC, Ahearn JM.

Immunol Res. 2006;36(1-3):3-12. Review.

PMID:
17337761
28.

Cell-bound complement activation products (CB-CAPs) as a source of lupus biomarkers.

Calano SJ, Shih PA, Liu CC, Kao AH, Navratil JS, Manzi S, Ahearn JM.

Adv Exp Med Biol. 2006;586:381-90. Review.

PMID:
16893085
29.

Platelet C4d is highly specific for systemic lupus erythematosus.

Navratil JS, Manzi S, Kao AH, Krishnaswami S, Liu CC, Ruffing MJ, Shaw PS, Nilson AC, Dryden ER, Johnson JJ, Ahearn JM.

Arthritis Rheum. 2006 Feb;54(2):670-4. Erratum in: Arthritis Rheum. 2006 Jun;54(6):2009.

30.

Reticulocytes bearing C4d as biomarkers of disease activity for systemic lupus erythematosus.

Liu CC, Manzi S, Kao AH, Navratil JS, Ruffing MJ, Ahearn JM.

Arthritis Rheum. 2005 Oct;52(10):3087-99.

31.

Biomarkers for systemic lupus erythematosus: a review and perspective.

Liu CC, Manzi S, Ahearn JM.

Curr Opin Rheumatol. 2005 Sep;17(5):543-9. Review.

PMID:
16093831
32.

Measurement of erythrocyte C4d and complement receptor 1 in systemic lupus erythematosus.

Manzi S, Navratil JS, Ruffing MJ, Liu CC, Danchenko N, Nilson SE, Krishnaswami S, King DE, Kao AH, Ahearn JM.

Arthritis Rheum. 2004 Nov;50(11):3596-604.

33.

New advances in measurement of complement activation: lessons of systemic lupus erythematosus.

Liu CC, Manzi S, Danchenko N, Ahearn JM.

Curr Rheumatol Rep. 2004 Oct;6(5):375-81. Review.

PMID:
15355750
34.
35.

Apoptosis and immune responses to self.

Navratil JS, Sabatine JM, Ahearn JM.

Rheum Dis Clin North Am. 2004 Feb;30(1):193-212. Review.

PMID:
15061575
36.

Complement as a source of biomarkers in systemic lupus erythematosus: past, present, and future.

Liu CC, Ahearn JM, Manzi S.

Curr Rheumatol Rep. 2004 Apr;6(2):85-8. Review. No abstract available.

PMID:
15016335
37.

Apoptosis, complement and systemic lupus erythematosus: a mechanistic view.

Liu CC, Navratil JS, Sabatine JM, Ahearn JM.

Curr Dir Autoimmun. 2004;7:49-86. Review.

PMID:
14719375
38.

Apoptosis of skeletal muscle cells and the pathogenesis of myositis: a perspective.

Liu CC, Ahearn JM.

Curr Rheumatol Rep. 2001 Aug;3(4):325-33. Review.

PMID:
11470052
39.

Apoptosis, clearance mechanisms, and the development of systemic lupus erythematosus.

Navratil JS, Ahearn JM.

Curr Rheumatol Rep. 2001 Jun;3(3):191-8. Review.

PMID:
11352787
40.

The globular heads of C1q specifically recognize surface blebs of apoptotic vascular endothelial cells.

Navratil JS, Watkins SC, Wisnieski JJ, Ahearn JM.

J Immunol. 2001 Mar 1;166(5):3231-9.

41.

Apoptosis and autoimmunity: complement deficiency and systemic lupus erythematosus revisited.

Navratil JS, Ahearn JM.

Curr Rheumatol Rep. 2000 Feb;2(1):32-8. Review.

PMID:
11123037
43.

Functional characterization of soluble and membrane-bound forms of vaccinia virus complement control protein (VCP).

Rosengard AM, Alonso LC, Korb LC, Baldwin WM 3rd, Sanfilippo F, Turka LA, Ahearn JM.

Mol Immunol. 1999 Jul;36(10):685-97.

PMID:
10509819
44.

Viral complement regulatory proteins.

Rosengard AM, Ahearn JM.

Immunopharmacology. 1999 May;42(1-3):99-106. Review.

PMID:
10408371
45.
47.

Mechanism of suppression of cell-mediated immunity by measles virus.

Karp CL, Wysocka M, Wahl LM, Ahearn JM, Cuomo PJ, Sherry B, Trinchieri G, Griffin DE.

Science. 1996 Jul 12;273(5272):228-31. Erratum in: Science 1997 Feb 21;275(5303):1053.

PMID:
8662504
48.

Antibody response to a T-dependent antigen requires B cell expression of complement receptors.

Croix DA, Ahearn JM, Rosengard AM, Han S, Kelsoe G, Ma M, Carroll MC.

J Exp Med. 1996 Apr 1;183(4):1857-64.

49.

Disruption of the Cr2 locus results in a reduction in B-1a cells and in an impaired B cell response to T-dependent antigen.

Ahearn JM, Fischer MB, Croix D, Goerg S, Ma M, Xia J, Zhou X, Howard RG, Rothstein TL, Carroll MC.

Immunity. 1996 Mar;4(3):251-62.

Supplemental Content

Loading ...
Support Center